ADMA Biologics’ Earnings Call Contradictions: McKesson Timeline, Bivigam Revenue Outlook, and R&D Spending Signals Don’t Align

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $124.4M, up 2% YOY
• EPS: $0.33 per diluted share (GAAP), up 11% YOY (adjusted net income up 8% YOY)
• Gross Margin: 69%, compared to 55% in the prior year period

Guidance:

• Total revenue for full year 2026 expected to be $530M to $560M.
• Adjusted EBITDA for full year 2026 expected to be $265M to $300M.
• Adjusted net income for full year 2026 expected to be $170M to $200M.
• Outlook assumes sustained competitive dynamics and pricing pressure in standard immune globulin market.
• Ascentive expected to remain principal driver of revenue growth, profitability, and cash generation.

Business Commentary:

Revenue and Utilization Growth:

• ADMA Biologics reported total revenue of $124.4 million for the second quarter of 2026, a 2% year-over-year increase. Ascentive revenue grew by 24% year-over-year to $102.9 million.
• The growth was driven by strong cash generation, increasing physician adoption, and improving commercial momentum, particularly with Ascentive's utilization strengthening throughout the quarter.

Profitability and Margin Expansion:

• The company's gross margin improved to 69% compared to 55% in the prior year period, and adjusted EBITDA increased by 22% year-over-year to $61.8 million.
• Margin expansion was primarily due to the continued incentive mix expansion and the ongoing benefits of the yield-enhanced manufacturing process.

Cash and Balance Sheet Strength:

• ADMA ended the quarter with approximately $136 million in cash and cash equivalents and maintained a net leverage ratio of less than half a turn.
• The strong financial position provides strategic flexibility for investments in commercial expansion, manufacturing initiatives, and pipeline development, supporting long-term growth.

Commercial Momentum and Market Positioning:

• Ascentive demand accelerated during the quarter, with June showing the strongest sequential utilization growth since the first half of 2024.
• The momentum was driven by increasing physician adoption, broader provider engagement, and new patient starts, further supported by a growing body of real-world evidence highlighting its clinical benefits.

Sentiment Analysis:

Overall Tone: Positive

• Management expressed confidence in accelerating demand for Ascentive, citing 'strong execution,' 'strong cash generation,' and 'improving commercial momentum.' They noted June had 'the strongest sequential month-over-month end-user growth' since H1 2024 and reiterated full-year guidance, stating they are 'confident in our ability to meet or exceed those expectations.' The tone was optimistic regarding growth drivers and financial strength.

Q&A:

• Question from Ryan (Firm Not Specified): What is the current thinking on how quickly orders associated with the McKesson deal might develop? How much overlap with existing customers? How do payment terms compare?
  Response: McKesson is part of the go-forward strategy; some GPO buying groups it serves are focused on secondary immune deficiency, which does not overlap with current call points. Utilization is good, and payment terms are faster than some other partners, but the partnership is positive.

• Question from Kristin Kluska (Cantor Fitzgerald): Can you provide new statistics or color on reimbursement dynamics for Ascentive and market dislocation?
  Response: No significant negative changes in reimbursement; Ascentive sees broad commercial access. Increased utilization is driven by real-world evidence. Bivigam demand stabilized sequentially but remains down YOY; competitive pressures persist in standard IG market.

• Question from Kristin Kluska (Cantor Fitzgerald): How should we think about R&D for the next few quarters as SG001 advances?
  Response: R&D stepped up in Q2 and is expected to carry through the year, with a potential step-up in Q4 as conformance batch manufacturing begins.

• Question from Anthony Petroni (Mizzou Financial Group): What is the visibility on when the traditional IG market (Bivigam) normalizes? Could there be modest growth for Bivigam in 2027?
  Response: Bivigam demand has stabilized, but guidance remains for it to be down 40-50% YOY in 2026. Potential upside exists but is not currently contemplated. Ascentive growth is expected to offset Bivigam's decline.

• Question from Anthony Petroni (Mizzou Financial Group): Could commercial payer access for Ascentive strengthen further? Any milestones to watch?
  Response: Ascentive and Bivigam are in parity with other IG brands, but robust discussions with payers are ongoing to secure improved access. Commercial payer book of business is increasing quarter-over-quarter.

• Question from Gary Nachman (Canaccord Genuity): Is the 2-4% monthly growth rate for Ascentive demand expected to continue, or could it be better? What drove the June acceleration?
  Response: June growth was outsized, but full-year guidance assumes a smoothed 2-4% month-over-month growth. Acceleration is driven by medical education, real-world data, and changing clinician mindsets, leading to increased patient starts and utilization.

• Question from Gary Nachman (Canaccord Genuity): Are you working on data in secondary immunodeficiency to boost uptake? How important is that for future growth?
  Response: Investigator-initiated studies in organ transplant and oncology are ongoing. For now, growth is driven by penetrating the refractory primary immunodeficiency market. Secondary immunodeficiency is a longer-term growth opportunity as the company expands into that segment.

Contradiction Point 1

McKesson Deal Duration and Continuity

Contradictory statements on the expected timeline and continuity of the McKesson partnership, impacting expectations for order development and revenue contribution.

Ryan (Cantor Fitzgerald) - Ryan (Cantor Fitzgerald)

2026Q2: The partnership is positive and expected to continue through the back half of 2026 into 2027. - Adam Grossman(CEO)

Can you provide an update on the McKesson deal regarding the speed of order development, customer overlap, and payment terms compared to other customers? - Ryan Deschner (Raymond James)

2026Q2: The partnership is going well and is expected to continue through the back half of 2026 into 2027. - Adam Grossman(CEO)

Contradiction Point 2

R&D Spending Trajectory for SG-001

Contradictory guidance on the timing and magnitude of future R&D expense increases, affecting financial planning and expectations for SG-001 development costs.

Kristin Kluska (Cantor Fitzgerald), what are your thoughts on the company's recent financial performance? - Kristin Kluska (Cantor Fitzgerald)

2026Q2: A further step-up in spending is anticipated in Q4, though not as large, to support the manufacturing of conformance batches. - Terry Kohler(CFO)

What's the outlook for R&D spending in the next few quarters as SG-001 advances? - Kristen Kluska (Cantor Fitzgerald)

2026Q2: There will likely be another step-up, though smaller, in Q4 as conformance lots are manufactured. - Terry Kohler(CFO)

Contradiction Point 3

McKesson Agreement Impact on Financials

Contradiction on the agreement's role in improving Days Sales Outstanding (DSO), affecting financial performance expectations.

Ryan (Cantor Fitzgerald) - Ryan (Cantor Fitzgerald)

2026Q2: The company is having productive conversations and seeing good utilization with decision-makers in this channel. McKesson's payment terms are faster than some other customers... - Adam Grossman(CEO)

Can you provide an update on the McKesson deal, including the expected speed of order development, overlap with existing customers, and how payment terms compare to other customers? - Gary Nachman (Canaccord Genuity)

2026Q1: Improvement in DSOs is expected in the back half of 2026. Key drivers include: 1) The growth of the McKesson specialty distribution agreement, which has favorable DSOs... - Terry Kohler(CFO)

Contradiction Point 4

Bivigam Demand Outlook

Contradiction on the current state and near-term outlook for Bivigam demand, influencing expectations for traditional immunoglobulin market recovery.

Anthony Petroni (Mizzou Financial Group) - Anthony Petroni (Mizzou Financial Group)

2026Q2: Bivigam demand has stabilized, though competitive dynamics persist... guidance remains conservative, anticipating Bivigam to be down 40-50% year-over-year in 2026. - Adam Grossman(CEO)

What is the visibility on when the traditional IG market (Bivigam) normalizes, and could Bivigam see modest growth in 2027? - Anthony Petrone (Mizuho Financial Group)

2026Q1: Signs of reversion are appearing: BIVIGAM utilization improved to its best month in April... - Adam Grossman(CEO)

Contradiction Point 5

Bivigam 2026 Revenue Outlook

Inconsistent guidance for Bivigam's 2026 performance between quarters, affecting financial forecasting and investment in the traditional IG segment.

What are Anthony Petroni's insights on Mizzou Financial Group's earnings performance? - Anthony Petroni (Mizzou Financial Group)

2026Q2: The company's guidance remains conservative, anticipating Bivigam to be down 40-50% year-over-year in 2026. - Adam Grossman(CEO)

What is the visibility on when the traditional IG market (Bivigam) normalizes and could Bivigam see modest growth in 2027? - Rick Miller (Cantor Fitzgerald)

20260226-2025 Q4: BIVIGAM is forecasted to be flat to down in 2026. - Adam Grossman(CEO)

<<>>